HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Returning Zantac OTC Heartburn Remedy Brand To US Market Formulated With Famotidine

Consumer Health Gets Little Mention In Q1 Results After Sales Dip 7%

Executive Summary

Along with its Q1 results including a 7.3% drop in consumer health sales to 1.11bn ($1.35bn), Sanofi announces 10-mg famotidine tablets branded Zantac 360° will be available in the US in June.

You may also be interested in...



Mint Flavor Harvest For OTC Famotidine Pioneer Pepcid AC Follows Two ANDA Competitors

Pepcid AC Maximum Strength (20 mg) in Icy Cool Mint tablets available in 20- and 40-count bottles. Walmart’s Equate and Sanofi’s Zantac 360 famotidine formulations already offer mint flavor options.

GSK Agreed To Settle California Zantac Litigation After Judge Cleared Plaintiff's Experts To Testify

State court judge would've allowed testimony from 13 of 14 witnesses plaintiff proposed as experts for trial scheduled to start in late July. Plaintiff’s attorneys said decision on experts “signals significant litigation on the horizon for GSK.”

California Prop 65 Complaints Against OTC Generics? Ranitidine Could Be First And Last Target

Marketers of copies of national brand OTCs are required under FDA regulations to use the same labeling as the brand, a rule that in effect has limited complaints in California state court alleging Prop 65 violations with nonprescription drug labeling to targeting branded product marketers.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel